KR860004056A - 실리비닌 유도체의 제조방법 - Google Patents

실리비닌 유도체의 제조방법 Download PDF

Info

Publication number
KR860004056A
KR860004056A KR1019850008733A KR850008733A KR860004056A KR 860004056 A KR860004056 A KR 860004056A KR 1019850008733 A KR1019850008733 A KR 1019850008733A KR 850008733 A KR850008733 A KR 850008733A KR 860004056 A KR860004056 A KR 860004056A
Authority
KR
South Korea
Prior art keywords
alk
silybinin
derivative
irrespective
general formula
Prior art date
Application number
KR1019850008733A
Other languages
English (en)
Other versions
KR870001020B1 (ko
Inventor
브라쯔(외 4) 라인하르트
Original Assignee
원본미기재
독토르 마다우스 게젤샤프트 미트베쉬랭크테르 하우프퉁 운트 콤파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 독토르 마다우스 게젤샤프트 미트베쉬랭크테르 하우프퉁 운트 콤파니 filed Critical 원본미기재
Publication of KR860004056A publication Critical patent/KR860004056A/ko
Application granted granted Critical
Publication of KR870001020B1 publication Critical patent/KR870001020B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Silicon Compounds (AREA)

Abstract

내용 없음

Description

실리비닌 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 열적 피부손상으로 인한 마이크로솜 간지질 변화에 관한 지방산 분포를 나타낸다.
제2도는 임파구의 배자발생에 대한 Sili-suc-na의 영향을 나타낸다.

Claims (5)

1부의 하기 일반식(II)의 실리비닌을 1 내지 2부의 피리딘에 용해하고 교반중에 1 내지 3부의 하기 일반식(III)의 디카르복실 산안히드라이드와 반응시켜 에탄올을 가하여 균일한 혼합물을 만들고 연속적으로 물을 가하여서 방향족으로 결합된 수산기의 에스테르를 가수분해하고 이 가수분해가 완결되자마자 그 혼합물을 메틸아세테이트로 희석하고 산성화수로써 세척한후에 에틸아세테이트상을 증발시킨 잔사를 에탄올 취하여 알콜성알칼리금속 하이드록시드 용액을 사용, 유리카르복실산 잔기염으로 전환시키는 것을 특징으로 하는 하기 일반식(I)의 실리비닌 유도체의 제조방법.
(상기식들에서n과m은 서로 무관하게, 0 또는 1이며 Alk; Alk1과 Alk2는 서로 무관하게 4이하의 C원자를 가지는 알킬렌라디칼 또는 2 내지 4C원자를 가지는 알케닐렌 라디칼이며 M1과 M2는 서로 무관하게 수소원자 또는 알카리금속 원자임.)
제1항에 있어서, 디카르복실산 안히드라이드와의 반응이 약 40 내지 50℃의 온도에서 수행되는 것을 특징으로 하는 방법.
제1 또는 2항에 있어서, 그 에틸아세테이트-포화, 산성화수가 약 1.5 내지 2.4의 pH로 유지되는 것을 특징으로 하는 방법.
명세서 설명 예시된 바와같은 제1항의 실리비딘 유도체의 제조방법.
고체 또는 액체의 약제학적 희석제 또는 담체와 함께 일반식(I)의 실리비닌 유도체중 하나이상을 함유하는 것을 특징으로 하는 약학조성물.
(n,m, Alk1과 Alk2,M1과 M2는 제1항에서와 같음.)
※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850008733A 1984-11-22 1985-11-22 실리비닌 유도체의 제조방법 KR870001020B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3442639 1984-11-22
DE19843442639 DE3442639A1 (de) 1984-11-22 1984-11-22 Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten

Publications (2)

Publication Number Publication Date
KR860004056A true KR860004056A (ko) 1986-06-16
KR870001020B1 KR870001020B1 (ko) 1987-05-23

Family

ID=6250903

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850008733A KR870001020B1 (ko) 1984-11-22 1985-11-22 실리비닌 유도체의 제조방법

Country Status (29)

Country Link
JP (1) JPS61143377A (ko)
KR (1) KR870001020B1 (ko)
AR (1) AR240931A1 (ko)
AT (1) AT393268B (ko)
BE (1) BE903693A (ko)
CA (1) CA1337124C (ko)
CH (1) CH659473A5 (ko)
CS (1) CS273610B2 (ko)
DD (1) DD259191A1 (ko)
DE (1) DE3442639A1 (ko)
DK (1) DK164865C (ko)
EG (1) EG19424A (ko)
ES (1) ES8609311A1 (ko)
FI (1) FI84064C (ko)
FR (1) FR2573427B1 (ko)
GB (1) GB2167414B (ko)
HU (1) HU195503B (ko)
IE (1) IE58791B1 (ko)
IT (1) IT1190426B (ko)
LU (1) LU86163A1 (ko)
MX (1) MX168415B (ko)
NL (1) NL192387C (ko)
NO (1) NO160205C (ko)
PL (1) PL146890B1 (ko)
PT (1) PT81532B (ko)
SE (1) SE465676B (ko)
SU (1) SU1436875A3 (ko)
YU (1) YU43689B (ko)
ZA (1) ZA858951B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8716918D0 (en) * 1987-07-17 1987-08-26 Inverni Della Beffa Spa Soluble derivatives of silybin
US5262439A (en) * 1992-04-30 1993-11-16 The Regents Of The University Of California Soluble analogs of probucol
NZ560633A (en) * 2005-03-11 2011-08-26 Neuprotect Pty Ltd Flavonoid compounds and uses thereof
RU2482844C2 (ru) * 2007-11-15 2013-05-27 Мадаус Гмбх Силибининовый компонент для лечения гепатита
MX2010005107A (es) * 2007-11-15 2010-05-27 Madaus Gmbh Componente de silibinina para tratamiento contra hepatitis.
CA2761656C (en) 2009-05-14 2017-02-07 Lucio Claudio Rovati Amorphous silibinin for the treatment of viral hepatitis
CN108355136B (zh) 2012-07-05 2021-12-07 纽崔玛氏科技有限责任公司 包含莱菔硫烷或莱菔硫烷前体和蕈类提取物或粉末的组合物
CN103172622B (zh) * 2013-02-22 2015-11-04 西安安健药业有限公司 水飞蓟宾二偏琥珀酸酯的活性异构体
CN103193768B (zh) * 2013-02-22 2016-03-30 西安安健药业有限公司 治疗肝病的水飞蓟宾二偏琥珀酸酯异构体
CN103113359B (zh) * 2013-02-22 2016-01-06 西安安健药业有限公司 水飞蓟宾二偏琥珀酸酯及其药用盐

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963318A1 (de) * 1969-12-17 1971-06-24 Schwabe Willmar Gmbh & Co Silybinhalbester der Bernsteinsaeure und der Phthalsaeure,ihre Salze mit pharmakologisch vertraglichen Basen,Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneipraeparaten

Also Published As

Publication number Publication date
ZA858951B (en) 1986-08-27
YU178685A (en) 1988-02-29
PT81532B (pt) 1987-11-11
FI854535A0 (fi) 1985-11-18
DK537785D0 (da) 1985-11-21
NL192387B (nl) 1997-03-03
DK164865C (da) 1993-01-18
SE8505487D0 (sv) 1985-11-20
LU86163A1 (de) 1986-03-24
CS273610B2 (en) 1991-03-12
EG19424A (en) 1995-02-28
FR2573427A1 (fr) 1986-05-23
IE58791B1 (en) 1993-11-17
CS837885A2 (en) 1990-08-14
PT81532A (de) 1985-12-01
BE903693A (fr) 1986-05-22
CH659473A5 (de) 1987-01-30
IE852808L (en) 1986-05-22
SE8505487L (sv) 1986-05-23
CA1337124C (en) 1995-09-26
NO160205C (no) 1989-03-22
AT393268B (de) 1991-09-25
FR2573427B1 (fr) 1989-03-10
NL192387C (nl) 1997-07-04
ATA337185A (de) 1991-02-15
GB2167414A (en) 1986-05-29
HU195503B (en) 1988-05-30
DK537785A (da) 1986-05-23
HUT40114A (en) 1986-11-28
IT1190426B (it) 1988-02-16
ES8609311A1 (es) 1986-09-01
GB8528226D0 (en) 1985-12-18
MX168415B (es) 1993-05-24
NO160205B (no) 1988-12-12
YU43689B (en) 1989-10-31
ES549116A0 (es) 1986-09-01
DD259191A1 (de) 1988-08-17
NO854655L (no) 1986-05-23
NL8503171A (nl) 1986-06-16
PL256374A1 (en) 1986-12-02
DE3442639A1 (de) 1986-05-22
PL146890B1 (en) 1989-03-31
SE465676B (sv) 1991-10-14
SU1436875A3 (ru) 1988-11-07
IT8522932A0 (it) 1985-11-21
JPS61143377A (ja) 1986-07-01
FI84064B (fi) 1991-06-28
KR870001020B1 (ko) 1987-05-23
GB2167414B (en) 1989-01-11
AR240931A1 (es) 1991-03-27
FI854535A (fi) 1986-05-23
FI84064C (fi) 1991-10-10
AR240931A2 (es) 1991-03-27
DE3442639C2 (ko) 1989-08-10
JPH0432073B2 (ko) 1992-05-28
DK164865B (da) 1992-08-31

Similar Documents

Publication Publication Date Title
Shore et al. The crystalline compound ammonia-borane, 1 H3NBH3
KR850001199A (ko) 1,8-나프티리딘 유도체의 제조법
KR860004056A (ko) 실리비닌 유도체의 제조방법
DE19975059I2 (de) (2-Oxo-3-tetrahydrothienylcarbamoyl)-alkylthio-essigsäure, ihre Salze und Ester, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel.
KR840002350A (ko) N-아세틸시스테인의 살리실산 유도체의 제조 방법
KR860000236A (ko) 유기산의 트리테르페닐의 에스테르의 제조방법
KR830010039A (ko) 페닐 지방성 카복실린산 유도체의 제조방법
KR880006363A (ko) 카르복실산 에스테르의 제조법
KR850005453A (ko) 신규의 δ4-와 δ5-안드로스텐 유도체의 제조방법과 그것을 포함하는 약학적 조성물
KR850001766A (ko) 무라밀디펩타이드 활성 에스테르 유도체의 제조방법
Marker et al. Sterols. CXXXII. Sapogenins. LIV. The Action of Hydrogen Peroxide on the Pseudosapogenin Acetates and on the Pregnenolones
GB576314A (en) Cosmetic preparations
KR850001732A (ko) 소염작용 및 점액 용해작용을 갖는 ⅳ-아세틸시스테인 및 s-카르복시메틸시스테인의 2',4'-디플루오로-4-히드록시-(1,1'-디페닐)-3-카르복실산 유도체의 제조방법
ES428213A1 (es) Procedimiento para la obtencion de esteres dialquilaminoal-quilicos de penicilina.
ES405644A1 (es) Procedimiento para la preparacion de nuevos acidos 4 - (4 -bifenilil) - 4 - hidroxi - butiricos, sus esteres o lacto- nas.
US3185702A (en) Basic esters of 3-aryl-3-pyrrolidinols
ES397453A1 (es) Procedimiento para la preparacion de derivados de imidazo- lina.
GB2001974A (en) Vincinic acid derivatives and process for the preparation thereof
Blankenstein et al. Some Derivatives of 8-Methylquinoline1
KR850006428A (ko) 에리드로마이신 아세트산염의 제조방법
KR880002800A (ko) 시클로헥산온 카르복실산류의 제조방법
GB741250A (en) Vitamin b derivatives and a method of preparing same
JPS6121469B2 (ko)
KR850001768A (ko) 아스팔릴-페닐알라닌메틸에스테르의 제조방법
KR890005050A (ko) 테트라히드로프탈이미드 화합물 제조

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20000512

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee